DYRK2 and ovarian carcinoma: For example, Choi et al. revealed that miR-622 induced resistance to PARPis and platinum in BRCA1-mutant ovarian cancer by targeting the Ku complex and restoring HR-mediated DSB repair [16]; Wang et al. reported that miR-622 targeted DYRK2 to promote the migration and invasion of colorectal cancer [17]; while Liu et al. found that EZH2 inhibited the targeted regulation of miR-622 to upregulate CXCR4 and promote HCC tumorigenesis [13].